APA (7th ed.) Citation

K, C., SJ, P., BI, M., CS, D., NH, N., JM, D., . . . PS, R. (2023). Clinical Utility of Genomic Recurrence Risk Stratification in Early, Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Real-World Experience. Clinical breast cancer, 23(2), 155. https://doi.org/10.1016/j.clbc.2022.11.005

Chicago Style (17th ed.) Citation

K, Choucair, et al. "Clinical Utility of Genomic Recurrence Risk Stratification in Early, Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Real-World Experience." Clinical Breast Cancer 23, no. 2 (2023): 155. https://doi.org/10.1016/j.clbc.2022.11.005.

MLA (9th ed.) Citation

K, Choucair, et al. "Clinical Utility of Genomic Recurrence Risk Stratification in Early, Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Real-World Experience." Clinical Breast Cancer, vol. 23, no. 2, 2023, p. 155, https://doi.org/10.1016/j.clbc.2022.11.005.